Work

Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy

Year: 2024

Type: article

Abstract: Combination immune-checkpoint inhibition with chemotherapy is a clinical standard, yet concurrent administration may limit the full benefit of immunotherapy by blunting the proliferation and differentiation of CD8 T cells. Identifying patients in whom sequential chemo-immunotherapy or immunotherapy alone is feasible should be a priority to optimize long-term outcomes. See related article by Mariniello et al., p. 1833.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-23-3736

Authors: Paolo D.A. Vignali, Jason J. Luke

Institutions: University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Institute of Dental and Craniofacial Research